Transcriptomic analysis of the activity of a novel polymyxin against Staphylococcus aureus

mSphere

Volumn 1, Issue 4, 2016, Pages

  Zhao, Jinxin ^a,b   Cheah, Soon Ee ^a   Roberts, Kade D ^b   Nation, Roger L ^b   Thompson, Philip E ^b   Velkov, Tony ^b   Du, Zongjun ^a   Johnson, Matthew D ^b   Li, Jian ^b  

^a SHANDONG UNIVERSITY   (China)

^b MONASH UNIVERSITY   (Australia)

Author keywords

Gene expression; Polymyxins; Staphylococcus aureus

Indexed keywords

EID: 85011841148     PISSN: None     EISSN: 23795042     Source Type: Journal    
DOI: 10.1128/mSphere.00119-16     Document Type: Article

References (63)

1. Hancock RE. 1997. Peptide antibiotics. Lancet 349:418-422. http:// dx.doi.org/10.1016/S0140-6736(97)80051-7
2. Hancock RE, Lehrer R. 1998. Cationic peptides: a new source of antibiotics. Trends Biotechnol 16:82-88. http://dx.doi.org/10.1016/S0167-7799(97)01156-6
3. Velkov T, Roberts KD, Nation RL, Thompson PE, Li J. 2013. Pharmacology of polymyxins: new insights into an "old" class of antibiotics. Future Microbiol 8:711-724. http://dx.doi.org/10.2217/fmb.13.39
4. Azad MA, Huang JX, Cooper MA, Roberts KD, Thompson PE, Nation RL, Li J, Velkov T. 2012. Structure-activity relationships for the binding of polymyxins with human alpha-1-acid glycoprotein. Biochem Pharmacol 84:278-291. http://dx.doi.org/10.1016/j.bcp.2012.05.004
5. Powers JP, Hancock RE. 2003. The relationship between peptide structure and antibacterial activity. Peptides 24:1681-1691. http://dx.doi.org/ 10.1016/j.peptides.2003.08.023
6. Meredith JJ, Dufour A, Bruch MD. 2009. Comparison of the structure and dynamics of the antibiotic peptide polymyxin B and the inactive nonapeptide in aqueous trifluoroethanol by NMR spectroscopy. J Phys Chem B 113:544-551. http://dx.doi.org/10.1021/jp808379x
7. Brogden KA. 2005. Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria? Nat Rev Microbiol 3:238-250. http://dx.doi.org/ 10.1038/nrmicro1098
8. Hancock RE, Diamond G. 2000. The role of cationic antimicrobial peptides in innate host defences. Trends Microbiol 8:402-410. http:// dx.doi.org/10.1016/S0966-842X(00)01823-0
9. Velkov T, Roberts KD, Nation RL, Wang J, Thompson PE, Li J. 2014. Teaching "old" polymyxins new tricks: new-generation lipopeptides targeting gram-negative "superbugs." ACS Chem Biol 9:1172-1177. http:// dx.doi.org/10.1021/cb500080r
10. Rabanal F, Grau-Campistany A, Vila-Farrés X, Gonzalez-Linares J, Borràs M, Vila J, Manresa A, Cajal Y. 2015. A bioinspired peptide scaffold with high antibiotic activity and low in vivo toxicity. Sci Rep 5:10558. http://dx.doi.org/10.1038/srep10558
11. Gallardo-Godoy A, Muldoon C, Becker B, Elliott AG, Lash LH, Huang JX, Butler MS, Pelingon R, Kavanagh AM, Ramu S, Phetsang W, Blaskovich MA, Cooper MA. 2016. Activity and predicted nephrotoxicity of synthetic antibiotics based on polymyxin B. J Med Chem 59: 1068-1077. http://dx.doi.org/10.1021/acs.jmedchem.5b01593
12. Grau-Campistany A, Manresa á, Pujol M, Rabanal F, Cajal Y. 2016. Tryptophan-containing lipopeptide antibiotics derived from polymyxin B with activity against Gram positive and Gram negative bacteria. Biochim Biophys Acta 1858:333-343. http://dx.doi.org/10.1016/ j.bbamem.2015.11.011
13. Macfarlane EL, Kwasnicka A, Hancock RE. 2000. Role of Pseudomonas aeruginosa PhoP-PhoQ in resistance to antimicrobial cationic peptides and aminoglycosides. Microbiology 146:2543-2554. http://dx.doi.org/ 10.1099/00221287-146-10-2543
14. Dalebroux ZD, Matamouros S, Whittington D, Bishop RE, Miller SI. 2014. PhoPQ regulates acidic glycerophospholipid content of the Salmonella Typhimurium outer membrane. Proc Natl Acad Sci U S A 111:1963-1968. http://dx.doi.org/10.1073/pnas.1316901111
15. Llobet E, Campos MA, Giménez P, Moranta D, Bengoechea JA. 2011. Analysis of the networks controlling the antimicrobial-peptidedependent induction of Klebsiella pneumoniae virulence factors. Infect Immun 79:3718-3732. http://dx.doi.org/10.1128/IAI.05226-11
16. Lee H, Hsu FF, Turk J, Groisman EA. 2004. The PmrA-regulated pmrC gene mediates phosphoethanolamine modification of lipid A and polymyxin resistance in Salmonella enterica. J Bacteriol 186:4124-4133. http://dx.doi.org/10.1128/JB.186.13.4124-4133.2004
17. Arroyo LA, Herrera CM, Fernandez L, Hankins JV, Trent MS, Hancock RE. 2011. The pmrCAB operon mediates polymyxin resistance in Acinetobacter baumannii ATCC 17978 and clinical isolates through phosphoethanolamine modification of lipid A. Antimicrob Agents Chemother 55:3743-3751. http://dx.doi.org/10.1128/AAC.00256-11
18. Cheng HY, Chen YF, Peng HL. 2010. Molecular characterization of the PhoPQ-PmrD-PmrAB mediated pathway regulating polymyxin B resistance in Klebsiella pneumoniae CG43. J Biomed Sci 17:60. http:// dx.doi.org/10.1186/1423-0127-17-60
19. Kim SY, Choi HJ, Ko KS. 2014. Differential expression of twocomponent systems, pmrAB and phoPQ, with different growth phases of Klebsiella pneumoniae in the presence or absence of colistin. Curr Microbiol 69:37-41. http://dx.doi.org/10.1007/s00284-014-0549-0
20. Helander IM, Kato Y, Kilpeläinen I, Kostiainen R, Lindner B, Nummila K, Sugiyama T, Yokochi T. 1996. Characterization of lipopolysaccharides of polymyxin-resistant and polymyxin-sensitive Klebsiella pneumoniae O3. Eur J Biochem 237:272-278. http://dx.doi.org/10.1111/ j.1432-1033.1996.0272n.x
21. Pietiäinen M, Gardemeister M, Mecklin M, Leskelä S, Sarvas M, Kontinen VP. 2005. Cationic antimicrobial peptides elicit a complex stress response in Bacillus subtilis that involves ECF-type sigma factors and two-component signal transduction systems. Microbiology 151: 1577-1592. http://dx.doi.org/10.1099/mic.0.27761-0
22. Pietiäinen M, François P, Hyyryläinen HL, Tangomo M, Sass V, Sahl HG, Schrenzel J, Kontinen VP. 2009. Transcriptome analysis of the responses of Staphylococcus aureus to antimicrobial peptides and characterization of the roles of vraDE and vraSR in antimicrobial resistance. BMC Genomics 10:429. http://dx.doi.org/10.1186/1471-2164-10-429
23. Henry R, Vithanage N, Harrison P, Seemann T, Coutts S, Moffatt JH, Nation RL, Li J, Harper M, Adler B, Boyce JD. 2012. Colistin-resistant, lipopolysaccharide-deficient Acinetobacter baumannii responds to lipopolysaccharide loss through increased expression of genes involved in the synthesis and transport of lipoproteins, phospholipids, and polybeta-1,6-N-acetylglucosamine. Antimicrob Agents Chemother 56: 59-69. http://dx.doi.org/10.1128/AAC.05191-11
24. Henry R, Crane B, Powell D, Deveson Lucas D, Li Z, Aranda J, Harrison P, Nation RL, Adler B, Harper M, Boyce JD, Li J. 2015. The transcriptomic response of Acinetobacter baumannii to colistin and doripenem alone and in combination in an in vitro pharmacokinetics/ pharmacodynamics model. J Antimicrob Chemother 70:1303-1313. http://dx.doi.org/10.1093/jac/dku536
25. Li J, Turnidge J, Milne R, Nation RL, Coulthard K. 2001. In vitro pharmacodynamic properties of colistin and colistin methanesulfonate against Pseudomonas aeruginosa isolates from patients with cystic fibrosis. Antimicrob Agents Chemother 45:781-785. http://dx.doi.org/ 10.1128/AAC.45.3.781-785.2001
26. Poudyal A, Howden BP, Bell JM, Gao W, Owen RJ, Turnidge JD, Nation RL, Li J. 2008. In vitro pharmacodynamics of colistin against multidrug-resistant Klebsiella pneumoniae. J Antimicrob Chemother 62: 1311-1318. http://dx.doi.org/10.1093/jac/dkn425
27. Tan CH, Li J, Nation RL. 2007. Activity of colistin against heteroresistant Acinetobacter baumannii and emergence of resistance in an in vitro pharmacokinetic/pharmacodynamic model. Antimicrob Agents Chemother 51:3413-3415. http://dx.doi.org/10.1128/AAC.01571-06
28. Li J, Rayner CR, Nation RL, Owen RJ, Spelman D, Tan KE, Liolios L. 2006. Heteroresistance to colistin in multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 50:2946-2950. http:// dx.doi.org/10.1128/AAC.00103-06
29. Jothi R, Balaji S, Wuster A, Grochow JA, Gsponer J, Przytycka TM, Aravind L, Babu MM. 2009. Genomic analysis reveals a tight link between transcription factor dynamics and regulatory network architecture. Mol Syst Biol 5:294. http://dx.doi.org/10.1038/msb.2009.52
30. Kuroda H, Kuroda M, Cui L, Hiramatsu K. 2007. Subinhibitory concentrations of beta-lactam induce haemolytic activity in Staphylococcus aureus through the SaeRS two-component system. FEMS Microbiol Lett 268:98-105. http://dx.doi.org/10.1111/j.1574-6968.2006.00568.x
31. Rogasch K, Rühmling V, Pané-Farré J, Höper D, Weinberg C, Fuchs S, Schmudde M, Bröker BM, Wolz C, Hecker M, Engelmann S. 2006. Influence of the two-component system SaeRS on global gene expression in two different Staphylococcus aureus strains. J Bacteriol 188: 7742-7758. http://dx.doi.org/10.1128/JB.00555-06
32. Jeong DW, Cho H, Jones MB, Shatzkes K, Sun F, Ji Q, Liu Q, Peterson SN, He C, Bae T. 2012. The auxiliary protein complex SaePQ activates the phosphatase activity of sensor kinase SaeS in the SaeRS twocomponent system of Staphylococcus aureus. Mol Microbiol 86:331-348. http://dx.doi.org/10.1111/j.1365-2958.2012.08198.x
33. Haupt K, Reuter M, van den Elsen J, Burman J, Hälbich S, Richter J, Skerka C, Zipfel PF. 2008. The Staphylococcus aureus protein Sbi acts as a complement inhibitor and forms a tripartite complex with host complement factor H and C3b. PLoS Pathog 4:e1000250. http://dx.doi.org/ 10.1371/journal.ppat.1000250
34. Arciola CR, Campoccia D, Gamberini S, Baldassarri L, Montanaro L. 2005. Prevalence of cna, fnbA and fnbB adhesin genes among Staphylococcus aureus isolates from orthopedic infections associated to different types of implant. FEMS Microbiol Lett 246:81-86. http://dx.doi.org/ 10.1016/j.femsle.2005.03.035
35. Lou Q, Zhu T, Hu J, Ben H, Yang J, Yu F, Liu J, Wu Y, Fischer A, Francois P, Schrenzel J, Qu D. 2011. Role of the SaeRS two-component regulatory system in Staphylococcus epidermidis autolysis and biofilm formation. BMC Microbiol 11:146. http://dx.doi.org/10.1186/1471-2180-11-146
36. Collery MM, Smyth CJ. 2007. Rapid differentiation of Staphylococcus aureus isolates harbouring egc loci with pseudogenes ψent1 and ψent2 and the selu or seluv gene using PCR-RFLP. J Med Microbiol 56:208-216. http://dx.doi.org/10.1099/jmm.0.46948-0
37. Jelsbak L, Thomsen LE, Wallrodt I, Jensen PR, Olsen JE. 2012. Polyamines are required for virulence in Salmonella enterica serovar Typhimurium. PLoS One 7:e36149. http://dx.doi.org/10.1371/ journal.pone.0036149
38. Soksawatmaekhin W, Kuraishi A, Sakata K, Kashiwagi K, Igarashi K. 2004. Excretion and uptake of cadaverine by CadB and its physiological functions in Escherichia coli. Mol Microbiol 51:1401-1412. http:// dx.doi.org/10.1046/j.1365-2958.2003.03913.x
39. Umbarger HE. 1978. Amino acid biosynthesis and its regulation. Annu Rev Biochem 47:533-6 0 6 . h t t p: / / d x . d o i . o r g / 1 0 . 1 1 4 6 / annurev.bi.47.070178.002533
40. Wüst J, Wilkins TD. 1978. Susceptibility of anaerobic bacteria to sulfamethoxazole/trimethoprim and routine susceptibility testing. Antimicrob Agents Chemother 14:384-390. http://dx.doi.org/10.1128/ AAC.14.3.384
41. Evans ME, Feola DJ, Rapp RP. 1999. Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant gram-negative bacteria. Ann Pharmacother 33:960-967. http://dx.doi.org/10.1345/aph.18426
42. Finegold SM, Davis A, Ziment I, Jacobs I. 1969. Chemotherapy guide. Calif Med 111:362
43. Zavascki AP, Goldani LZ, Li J, Nation RL. 2007. Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review. J Antimicrob Chemother 60:1206-1215. http://dx.doi.org/10.1093/jac/dkm357
44. Bergen PJ, Bulman ZP, Saju S, Bulitta JB, Landersdorfer C, Forrest A, Li J, Nation RL, Tsuji BT. 2015. Polymyxin combinations: pharmacokinetics and pharmacodynamics for rationale use. Pharmacotherapy 35: 34-42. http://dx.doi.org/10.1002/phar.1537
45. Nation RL, Li J, Cars O, Couet W, Dudley MN, Kaye KS, Mouton JW, Paterson DL, Tam VH, Theuretzbacher U, Tsuji BT, Turnidge JD. 2015. Framework for optimisation of the clinical use of colistin and polymyxin B: the Prato polymyxin consensus. Lancet Infect Dis 15: 225-234. http://dx.doi.org/10.1016/S1473-3099(14)70850-3
46. Mulcahy H, Charron-Mazenod L, Lewenza S. 2008. Extracellular DNA chelates cations and induces antibiotic resistance in Pseudomonas aeruginosa biofilms. PLoS Pathog 4:e1000213. http://dx.doi.org/10.1371/ journal.ppat.1000213
47. Moffatt JH, Harper M, Adler B, Nation RL, Li J, Boyce JD. 2011. Insertion sequence ISAba11 is involved in colistin resistance and loss of lipopolysaccharide in Acinetobacter baumannii. Antimicrob Agents Chemother 55:3022-3024. http://dx.doi.org/10.1128/AAC.01732-10
48. Zhou Z, Ribeiro AA, Lin S, Cotter RJ, Miller SI, Raetz CR. 2001. Lipid A modifications in polymyxin-resistant Salmonella typhimurium: PMRAdependent 4-amino-4-deoxy-L-arabinose, and phosphoethanolamine incorporation. J Biol Chem 276:43111-43121. http://dx.doi.org/10.1074/ jbc.M106960200
49. Beceiro A, Llobet E, Aranda J, Bengoechea JA, Doumith M, Hornsey M, Dhanji H, Chart H, Bou G, Livermore DM, Woodford N. 2011. Phosphoethanolamine modification of lipid A in colistin-resistant variants of Acinetobacter baumannii mediated by the pmrAB twocomponent regulatory system Antimicrob Agents Chemother 55: 3370-3379. http://dx.doi.org/10.1128/AAC.00079-11
50. Moffatt JH, Harper M, Mansell A, Crane B, Fitzsimons TC, Nation RL, Li J, Adler B, Boyce JD. 2013. Lipopolysaccharide-deficient Acinetobacter baumannii shows altered signaling through host Toll-like receptors and increased susceptibility to the host antimicrobial peptide LL-37. Infect Immun 81:684-689. http://dx.doi.org/10.1128/IAI.01362-12
51. Owen RJ, Li J, Nation RL, Spelman D. 2007. In vitro pharmacodynamics of colistin against Acinetobacter baumannii clinical isolates. J Antimicrob Chemother 59:473-477. http://dx.doi.org/10.1093/jac/dkl512
52. Abdul Rahim N, Cheah SE, Johnson MD, Yu H, Sidjabat HE, Boyce J, Butler MS, Cooper MA, Fu J, Paterson DL, Nation RL, Bergen PJ, Velkov T, Li J. 2015. Synergistic killing of NDM-producing MDR Klebsiella pneumoniae by two "old" antibiotics-polymyxin B and chloramphenicol. J Antimicrob Chemother 70:2589-2597. http://dx.doi.org/10.1093/jac/ dkv135
53. Hartmann M, Berditsch M, Hawecker J, Ardakani MF, Gerthsen D, Ulrich AS. 2010. Damage of the bacterial cell envelope by antimicrobial peptides gramicidin S and PGLa as revealed by transmission and scanning electron microscopy. Antimicrob Agents Chemother 54:3132-3142. http://dx.doi.org/10.1128/AAC.00124-10
54. Belcheva A, Golemi-Kotra D. 2008. A close-up view of the VraSR two-component system. A mediator of Staphylococcus aureus response to cell wall damage. J Biol Chem 283:12354-12364. http://dx.doi.org/ 10.1074/jbc.M710010200
55. Gardan R, Besset C, Guillot A, Gitton C, Monnet V. 2009. The oligopeptide transport system is essential for the development of natural competence in streptococcus thermophilus strain LMD-9. J Bacteriol 191: 4647-4655. http://dx.doi.org/10.1128/JB.00257-09
56. Howden BP, Peleg AY, Stinear TP. 2014. The evolution of vancomycin intermediate Staphylococcus aureus (VISA) and heterogenous-VISA. Infect Genet Evol 21:575-582. http://dx.doi.org/10.1016/ j.meegid.2013.03.047
57. Sieradzki K, Leski T, Dick J, Borio L, Tomasz A. 2003. Evolution of a vancomycin-intermediate Staphylococcus aureus strain in vivo: multiple changes in the antibiotic resistance phenotypes of a single lineage of methicillin-resistant S. aureus under the impact of antibiotics administered for chemotherapy. J Clin Microbiol 41:1687-1693. http:// dx.doi.org/10.1128/JCM.41.4.1687-1693.2003
58. Sopirala MM, Mangino JE, Gebreyes WA, Biller B, Bannerman T, Balada-Llasat JM, Pancholi P. 2010. Synergy testing by Etest, microdilution checkerboard, and time-kill methods for pan-drug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 54:4678-4683. http://dx.doi.org/10.1128/AAC.00497-10
59. Bergen PJ, Forrest A, Bulitta JB, Tsuji BT, Sidjabat HE, Paterson DL, Li J, Nation RL. 2011. Clinically relevant plasma concentrations of colistin in combination with imipenem enhance pharmacodynamic activity against multidrug-resistant Pseudomonas aeruginosa at multiple inocula. Antimicrob Agents Chemother 55:5134-5142. http:// dx.doi.org/10.1128/AAC.05028-11
60. Law CW, Chen Y, Shi W, Smyth GK. 2014. voom: Precision weights unlock linear model analysis tools for RNA-seq read counts. Genome Biol 15:R29. http://dx.doi.org/10.1186/gb-2014-15-2-r29
61. Liu R, Holik AZ, Su S, Jansz N, Chen K, Leong HS, Blewitt ME, Asselin-Labat ML, Smyth GK, Ritchie ME. 2015. Why weight? Modelling sample and observational level variability improves power in RNA-seq analyses. Nucleic Acids Res 43:e97. http://dx.doi.org/10.1093/nar/gkv412
62. Jombart T. 2008. adegenet: a R package for the multivariate analysis of genetic markers. Bioinformatics 24:1403-1405. http://dx.doi.org/ 10.1093/bioinformatics/btn129
63. Clinical and Laboratory Standards Institute. 2015. Performance standards for antimicrobial susceptibility testing; twenty-fifth informational supplement. Approved standard M100-S25. CLSI, Wayne, PA